*Disclaimer

ARGENICA THERAPEUTICS LIMITED (ASX: AGN)

🔗 📄 📈

AGN: ARG-007 Phase 2 Clinical Trial Update

ARGENICA THERAPEUTICS LIMITED

2023-07-19 08:23:00

AGN: ARG-007 Protects Brain Cells in Moderate TBI Model

ARGENICA THERAPEUTICS LIMITED

2023-06-22 08:19:00

AGN: Argenica Successfully Completes $4.0m Placement

ARGENICA THERAPEUTICS LIMITED

2023-06-02 09:29:00

AGN: Final Phase1 Clinical Trial Report

ARGENICA THERAPEUTICS LIMITED

2023-05-15 08:22:00

AGN: Latest Preclinical HIE Study Results

ARGENICA THERAPEUTICS LIMITED

2023-04-20 08:13:00

AGN: Significant Non-Dilutive Funding For Preclinical HIE Studies

ARGENICA THERAPEUTICS LIMITED

2023-03-30 09:28:00

AGN: Interim Phase 1 Safety Report Confirms Safety of ARG-007

ARGENICA THERAPEUTICS LIMITED

2023-03-06 08:16:00

AGN: Non-Dilutive Funding Received to Progress Alzheimers Studies

ARGENICA THERAPEUTICS LIMITED

2023-02-22 08:06:00

AGN: Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers

ARGENICA THERAPEUTICS LIMITED

2023-02-09 08:16:00

AGN: Argenica Awarded $1.2m CRC-P Grant for TBI Project

ARGENICA THERAPEUTICS LIMITED

2023-01-20 09:15:00